Timothy Dec compensation by year
Supernus Pharmaceuticals Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $135,096 | $412,500 | $453,800 | $485,500 | $504,900 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $151,190 | $726,000 | $658,200 | $315,040 |
| Option awards | $1,238,685 | $476,750 | $953,600 | $864,507 | $822,429 |
| Non-equity incentive | $72,300 | $178,200 | $210,588 | $229,160 | $233,894 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $7,454 | $44,730 | $39,639 | $40,264 | $40,146 |
| Total | $1,453,535 | $1,263,370 | $2,383,627 | $2,277,631 | $1,916,409 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Supernus Pharmaceuticals, Inc. DEF 14A filed April 30, 2026, accession 0001104659-26-053111, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Supernus Pharmaceuticals, Inc. filed document, accession 0001104659-26-053111. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 10,200 | $506,940 | — |
| RSU | 9,000 | $447,300 | — |
| RSU | 5,000 | $248,500 | — |
| PSU | 5,000 | $248,500 | — |
| RSU | 4,500 | $223,650 | — |
| RSU | 500 | $24,850 | — |
| Option | 6,250 | — | $32.20 |
| Option | 20,000 | — | $38.60 |
| Option | 37,500 | — | $27.94 |
| Option | 40,000 | — | $33.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Supernus Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
37 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-02 | Other | — | 14,059 | $0.00 | 14,059 |
| 2026-11-02 | Other derivative | — | 130,908 | $0.00 | 130,908 |
| 2026-11-02 | Other derivative | — | 38,502 | $0.00 | 38,502 |
| 2026-11-02 | Other derivative | — | 61,604 | $0.00 | 61,604 |
| 2026-11-02 | Other derivative | — | 77,005 | $0.00 | 77,005 |
| 2026-11-02 | Other derivative | — | 61,604 | $0.00 | 61,604 |
| 2026-11-02 | Other derivative | — | 26,951 | $0.00 | 26,951 |
| 2026-11-02 | Other derivative | — | 3,850 | $0.00 | 3,850 |
The 8 most recent of 37 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Supernus Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joe Ciaffoni | Chief Executive Officer | $18,501,214 |
| Jack Khattar | Chief Executive Officer, President & Secretary | $15,501,557 |
| Pat Barry | Chief Commercial Officer | $4,905,744 |
| Christian Heidbreder | Chief Scientific Officer | $4,182,548 |
| Richard Simkin | Former Chief Commercial Officer | $4,017,316 |
| Ryan Preblick | Chief Financial Officer | $3,592,393 |
| Jeff Burris | Chief Legal Officer | $3,521,215 |
| Mark Crossley | Former Chief Executive Officer | $3,185,591 |
| Timothy Dec · this page | Senior Vice President, Chief Financial Officer | $1,916,409 |
| Jonathan Rubin | Senior Vice President, Chief Medical Officer Research and Development | $1,448,731 |
| Padmanabh Bhatt | Senior Vice President, Intellectual Property, Chief Scientific Officer | $1,391,429 |
| Frank Mottola | Senior Vice President, Chief Technical Operations Officer | $1,360,701 |
Timothy Dec's compensation dossier, Supernus Pharmaceuticals
You have read Timothy Dec's totals and holdings. The dossier adds each equity grant Supernus Pharmaceuticals disclosed for Timothy Dec and Supernus Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Supernus Pharmaceuticals compensation record
free company briefThis page is one person within Supernus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Supernus Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Supernus Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Supernus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order SUPN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.